The Arrowhead Pharmaceuticals, Inc. Expected to

The Arrowhead Pharmaceuticals, Inc. Expected to Post FY2018 Earnings of ($0.93) Per Share (ARWR)
February 4, 2017 Jamie Williams
The Arrowhead Pharmaceuticals, Inc. Expected to Post FY2018 Earnings of ($0.93) Per Share (ARWR)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Cantor Fitzgerald issued their FY2018 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a note issued to investors on Tuesday. Cantor Fitzgerald analyst E. Piros anticipates that the brokerage will post earnings of ($0.93) per share for the year. Cantor Fitzgerald has a “Hold” rating and a $1.00 price target on the stock.

A number of other research firms also recently issued reports on ARWR. Chardan Capital set a $10.00 price objective on Arrowhead Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, September 29th. Jefferies Group reissued a “hold” rating and issued a $2.00 target price (down from $5.00) on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, November 30th. William Blair cut Arrowhead Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $12.00 to $2.00 in a research note on Wednesday, November 30th. Finally, Piper Jaffray Companies cut Arrowhead Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $10.00 to $2.00 in a research note on Wednesday, November 30th. Five analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $2.81.

Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) traded down 5.07% during midday trading on Thursday, reaching $2.06. The company’s stock had a trading volume of 1,599,712 shares. The company’s market capitalization is $152.80 million. The stock has a 50 day moving average of $2.08 and a 200-day moving average of $5.28. Arrowhead Pharmaceuticals has a 1-year low of $1.20 and a 1-year high of $8.22.

Large investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC boosted its stake in Arrowhead Pharmaceuticals by 1.2% in the second quarter. ProShare Advisors LLC now owns 52,038 shares of the company’s stock worth $277,000 after buying an additional 616 shares in the last quarter. California State Teachers Retirement System boosted its stake in Arrowhead Pharmaceuticals by 0.7% in the second quarter. California State Teachers Retirement System now owns 126,906 shares of the company’s stock valued at $675,000 after buying an additional 852 shares during the period. BlackRock Group LTD boosted its stake in Arrowhead Pharmaceuticals by 4.7% in the third quarter. BlackRock Group LTD now owns 20,563 shares of the company’s stock valued at $152,000 after buying an additional 929 shares during the period. BlackRock Advisors LLC boosted its stake in Arrowhead Pharmaceuticals by 4.6% in the second quarter. BlackRock Advisors LLC now owns 27,943 shares of the company’s stock valued at $149,000 after buying an additional 1,232 shares during the period. Finally, Nationwide Fund Advisors boosted its stake in Arrowhead Pharmaceuticals by 4.6% in the second quarter. Nationwide Fund Advisors now owns 38,161 shares of the company’s stock valued at $203,000 after buying an additional 1,684 shares during the period. 40.69% of the stock is currently owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

I'm in it to win it!

NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.

I was born with it, I'm truly blessed!

Alway's searching for winners'